Document is current

Any future updates will be listed below

The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

Crossref DOI link: https://doi.org/10.1186/s13075-015-0651-0

Published Online: 2015-05-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark